DexCom (DXCM)
(Delayed Data from NSDQ)
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Zacks News
Medtronic (MDT) Q2 Earnings Beat Estimates, 2024 View Up
by Zacks Equity Research
Medtronic (MDT) Q2 results reflect broad strength across businesses and geographies, benefiting from durable fundamentals.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes.
Zimmer Biomet's (ZBH) Knee Sales Robust, Macro Woes Hurt
by Zacks Equity Research
Zimmer Biomet (ZBH) is working to strengthen its foothold in emerging markets that provide long-term opportunities for growth.
Boston Scientific (BSX) Closes the Relievant Medsystems Buyout
by Zacks Equity Research
Boston Scientific (BSX) expands the neuromodulation portfolio with the acquisition of Relievant Medsystems.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
STERIS' (STE) Healthcare segment continues to benefit from procedure volume recovery.
DexCom (DXCM) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
National Vision's (EYE) Market Expansion Aids, Inflation Ails
by Zacks Equity Research
National Vision (EYE) is expanding sales by the continued rollout of its remote medicine technology.
Myriad Genetics (MYGN) Expands Pharma Services With New Pact
by Zacks Equity Research
Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration.
Medtronic's (MDT) Symplicity Spyral RDN System Gets FDA Boost
by Zacks Equity Research
Medtronic (MDT) receives the FDA approval for Symplicity blood pressure procedure for the treatment of hypertension.
Paragon 28 (FNA) BEAST Cortical Fibers Launch Boosts Biologics
by Zacks Equity Research
Paragon 28's (FNA) BEAST Cortical Fibers' advanced processing capability ensures the preservation of native bone morphogenic proteins and other growth factors crucial for bone formation.
Zacks.com featured highlights include DexCom, Arthur J. Gallagher, Limbach and The Hartford Financial Services
by Zacks Equity Research
DexCom, Arthur J. Gallagher, Limbach and The Hartford Financial Services are part of the Zacks Screen of the Week article.
Nemaura (NMRD) to Expand in UK With Metabolic Health Program
by Zacks Equity Research
The latest program leverages Nemaura's (NMRD) world-first daily wear non-invasive CGM technology, providing individuals with real-time insights into their body's glucose dynamics.
What's in the Cards for Medtronic (MDT) in Q2 Earnings?
by Zacks Equity Research
Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal second-quarter performance.
Neogen's (NEOG) Innovation Aids, Currency Headwind Stays
by Zacks Equity Research
Neogen (NEOG) is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets.
Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Charles River (CRL) Widens CliniPrime GMP Suite With New Launch
by Zacks Equity Research
Charles River (CRL) brings CliniPrime Cryopreserved Leukopaks for cell therapy development and manufacturing.
4 Best Stocks Exhibiting Solid Earnings Growth
by Tirthankar Chakraborty
Invest in stocks such as DexCom (DXCM), Arthur J. Gallagher (AJG), Limbach (LMB) and Hartford Financial Services (HIG) for superb earnings growth.
Paragon 28 (FNA) New Staple System Expands Ankle Device Line
by Zacks Equity Research
Paragon 28's (FNA) JAWS Great White Staple System is claimed to have 400 times greater fatigue life compared to competitors under similar load conditions.
Omnicell's (OMCL) Portfolio Expansion Aids Amid Macro Woes
by Zacks Equity Research
Omnicell (OMCL) accelerates its shift to cloud-based solutions and tech-enabled services through the launch of Inventory Optimization Service and Central Pharmacy Dispensing Services.
QIAGEN (QGEN) Expands Sample Technologies Line With New Launch
by Zacks Equity Research
QIAGEN's (QGEN) latest launches will better address the special needs of researchers working with challenging samples, allowing them to work more efficiently.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) due to its technology and innovative solutions.
Illumina (ILMN) Launches Initiative on Pathogen Sequencing
by Zacks Equity Research
Illumina (ILMN) introduces a new initiative to drive more equitable access to genomics globally.
Alcon (ALC) Q3 Earnings Miss Estimates, Margins Increase
by Zacks Equity Research
Alcon (ALC) Q3 revenues increase year over year, driven by strength in Surgical and Vision Care segments.
Prestige Consumer's (PBH) Brand Building, Innovation Aid Growth
by Zacks Equity Research
Prestige Consumer's (PBH) long-term brand-building efforts, efficient marketing, channel development and innovation help the company to continually hold a leading market share position.
QIAGEN (QGEN) Launches QIAcuity Kits and Software Update
by Zacks Equity Research
QIAGEN's (QGEN) new QIAcuity kits are likely to expand application areas and foster digital PCR adoption.